These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 21084246)

  • 1. Effect of omeprazole on the concentration of interleukin-6 and transforming growth factor-β1 in patients receiving dual antiplatelet therapy after percutaneous coronary intervention.
    Hudzik B; Szkodzinski J; Danikiewicz A; Wilczek K; Romanowski W; Lekston A; Polonski L; Zubelewicz-Szkodzinska B
    Eur Cytokine Netw; 2010 Dec; 21(4):257-63. PubMed ID: 21084246
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship between baseline inflammatory markers, antiplatelet therapy, and adverse cardiac events after percutaneous coronary intervention: an analysis from the clopidogrel for the reduction of events during observation trial.
    Dosh K; Berger PB; Marso S; van Lente F; Brennan DM; Charnigo R; Topol EJ; Steinhubl S
    Circ Cardiovasc Interv; 2009 Dec; 2(6):503-12. PubMed ID: 20031767
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study.
    Gilard M; Arnaud B; Cornily JC; Le Gal G; Lacut K; Le Calvez G; Mansourati J; Mottier D; Abgrall JF; Boschat J
    J Am Coll Cardiol; 2008 Jan; 51(3):256-60. PubMed ID: 18206732
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel.
    Sibbing D; Morath T; Stegherr J; Braun S; Vogt W; Hadamitzky M; Schömig A; Kastrati A; von Beckerath N
    Thromb Haemost; 2009 Apr; 101(4):714-9. PubMed ID: 19350116
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prolonged dual antiplatelet therapy after percutaneous coronary intervention reduces ischemic events without affecting the need for repeat revascularization: insights from the CREDO trial.
    Brener SJ; Steinhubl SR; Berger PB; Brennan DM; Topol EJ;
    J Invasive Cardiol; 2007 Jul; 19(7):287-90. PubMed ID: 17620671
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of concomitant treatment with proton pump inhibitors and clopidogrel on clinical outcome in patients after coronary stent implantation.
    Tentzeris I; Jarai R; Farhan S; Brozovic I; Smetana P; Geppert A; Wojta J; Siller-Matula J; Huber K
    Thromb Haemost; 2010 Dec; 104(6):1211-8. PubMed ID: 20941464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Earlier application of loading doses of aspirin and clopidogrel decreases rate of recurrent cardiovascular ischemic events for patients undergoing percutaneous coronary intervention.
    Tang FK; Lin LJ; Hua N; Lu H; Qi Z; Tang XZ
    Chin Med J (Engl); 2012 Feb; 125(4):631-8. PubMed ID: 22490487
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clopidogrel in addition to aspirin reduces in-hospital major cardiac and cerebrovascular events in unselected patients with acute ST segment elevation myocardial.
    Zeymer U; Gitt A; Jünger C; Bauer T; Heer T; Koeth O; Mark B; Zahn R; Senges J; Gottwik M
    Thromb Haemost; 2008 Jan; 99(1):155-60. PubMed ID: 18217148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of prasugrel versus clopidogrel on outcomes among patients with acute coronary syndrome undergoing percutaneous coronary intervention without stent implantation: a TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet inhibitioN with prasugrel (TRITON)-Thrombolysis in Myocardial Infarction (TIMI) 38 substudy.
    Pride YB; Wiviott SD; Buros JL; Zorkun C; Tariq MU; Antman EM; Braunwald E; Gibson CM;
    Am Heart J; 2009 Sep; 158(3):e21-6. PubMed ID: 19699846
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of antiplatelet effects of a modified protocol by platelet aggregation in patients undergoing "one-stop" hybrid coronary revascularization.
    Gao P; Xiong H; Zheng Z; Li L; Gao R; Hu SS
    Platelets; 2010; 21(3):183-90. PubMed ID: 20201634
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of major bleeding with concomitant dual antiplatelet therapy after percutaneous coronary intervention in patients receiving long-term warfarin therapy.
    DeEugenio D; Kolman L; DeCaro M; Andrel J; Chervoneva I; Duong P; Lam L; McGowan C; Lee G; DeCaro M; Ruggiero N; Singhal S; Greenspon A
    Pharmacotherapy; 2007 May; 27(5):691-6. PubMed ID: 17461704
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of two-year clopidogrel + aspirin in abolishing the risk of very late thrombosis after drug-eluting stent implantation (from the TYCOON [two-year ClOpidOgrel need] study).
    Tanzilli G; Greco C; Pelliccia F; Pasceri V; Barillà F; Paravati V; Pannitteri G; Gaudio C; Mangieri E
    Am J Cardiol; 2009 Nov; 104(10):1357-61. PubMed ID: 19892050
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clopidogrel for prevention of major cardiac events after coronary stent implantation: 30-day and 6-month results in patients with smaller stents.
    Calver AL; Blows LJ; Harmer S; Dawkins KD; Gray HH; Morgan JH; Simpson IA
    Am Heart J; 2000 Sep; 140(3):483-91. PubMed ID: 10966552
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of comedication with proton pump inhibitors (PPIs) on post-interventional residual platelet aggregation in patients undergoing coronary stenting treated by dual antiplatelet therapy.
    Zuern CS; Geisler T; Lutilsky N; Winter S; Schwab M; Gawaz M
    Thromb Res; 2010 Feb; 125(2):e51-4. PubMed ID: 19781742
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined clopidogrel and proton pump inhibitor therapy is associated with higher cardiovascular event rates after percutaneous coronary intervention: a report from the BASKET trial.
    Burkard T; Kaiser CA; Brunner-La Rocca H; Osswald S; Pfisterer ME; Jeger RV;
    J Intern Med; 2012 Mar; 271(3):257-63. PubMed ID: 21726302
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual low response to acetylsalicylic acid and clopidogrel is associated with myonecrosis and stent thrombosis after coronary stent implantation.
    Eshtehardi P; Windecker S; Cook S; Billinger M; Togni M; Garachemani A; Meier B; Hess OM; Wenaweser P
    Am Heart J; 2010 May; 159(5):891-898.e1. PubMed ID: 20435201
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Benefit of clopidogrel according to timing of percutaneous coronary intervention in patients with acute coronary syndromes: further results from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study.
    Lewis BS; Mehta SR; Fox KA; Halon DA; Zhao F; Peters RJ; Keltai M; Budaj A; Yusuf S;
    Am Heart J; 2005 Dec; 150(6):1177-84. PubMed ID: 16338255
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anticoagulant and/or antiplatelet treatment in patients with atrial fibrillation after percutaneous coronary intervention. A single-center experience.
    Maegdefessel L; Schlitt A; Faerber J; Bond SP; Messow CM; Buerke M; Raaz U; Werdan K; Muenzel T; Weiss C
    Med Klin (Munich); 2008 Sep; 103(9):628-32. PubMed ID: 18813885
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bleeding risk associated with 1 year of dual antiplatelet therapy after percutaneous coronary intervention: Insights from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial.
    Aronow HD; Steinhubl SR; Brennan DM; Berger PB; Topol EJ;
    Am Heart J; 2009 Feb; 157(2):369-74. PubMed ID: 19185647
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomised determination of the Effect of Fluvastatin and Atorvastatin on top of dual antiplatelet treatment on platelet aggregation after implantation of coronary drug-eluting stents. The EFA-Trial.
    Wenaweser P; Eshtehardi P; Abrecht L; Zwahlen M; Schmidlin K; Windecker S; Meier B; Haeberli A; Hess OM
    Thromb Haemost; 2010 Sep; 104(3):554-62. PubMed ID: 20664903
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.